. . .for a biotech company in the same relative position that MNTA finds itself today?
I realize that each situation is unique; it's just that a forward P/E of 17 in this industry & sector seems low to me, as it probably does to most MNTA longs. And there may be reasons for it being low that have been discussed ad nauseam on this board; I'm not looking to rehash any of them.